New Study Links High Systemic Immune-Inflammation Index to Atopic Dermatitis Risk in Adults with BMI Less Than 30

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-12 16:30 GMT   |   Update On 2024-09-12 16:30 GMT

USA: A recent cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2006 reveals a significant association between systemic immune-inflammation index (SII) levels and the risk of atopic dermatitis in US adults.

This study, published in Frontiers in Medicine, highlights that an SII higher than 330 × 10^9/L correlates with an increased risk of atopic dermatitis, particularly among individuals with a body mass index (BMI) less than 30.

"In adults with a BMI under 30, a Systemic Immune-Inflammation Index exceeding 330 × 10^9/L is linked to a 44% increased risk of developing atopic dermatitis (OR, 1.44). This finding points to SII as a potential new risk factor for atopic dermatitis. Incorporating SII into diagnostic criteria could lead to earlier detection and more effective preventive management of the condition," the researchers reported.

Advertisement

The systemic immune-inflammation index, a marker that combines platelet, neutrophil, and lymphocyte counts to gauge systemic inflammation, has been studied in various contexts. Although numerous studies have observed a correlation between elevated SII and various diseases, research specifically exploring the relationship between SII and atopic dermatitis is still limited. To fill this knowledge gap, Qike Ding, Department of Dermatology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China, and colleagues seek to examine the association between SII and atopic dermatitis among outpatient US adults.

For this purpose, the researchers conducted a compensatory cross-sectional study using NHANES data from the 2001–2006 cycles. They employed sample-weighted multivariate logistic regression and performed stratified analyses of sub-groups to investigate the associations.

The study analyzed data from 31,509 NHANES participants between 2001 and 2006. After excluding those under 20, over 59, or missing SII data, and removing 10 with missing atopic dermatitis data, 9,097 participants were included.

The study led to the following findings:

  • Logistic regression analysis did not show a significant overall association between SII and atopic dermatitis after adjusting for covariates.
  • In the subgroup with a BMI under 30, both univariate and multivariate analyses revealed that an SII higher than 330 × 10^9/L was linked to an increased risk of atopic dermatitis.
  • In the crude model, the odds ratio was 1.53, and in the adjusted model, it was 1.47.
  • After controlling for all confounding factors, the association remained significant, with an odds ratio of 1.44.
  • There were no similar associations in participants with a BMI of 30 or higher.
  • Stratified analyses indicated no modifiers in the relationship between SII and atopic dermatitis for those with a BMI under 30.
  • Missing data rates were low (0 to 4.8%), so no imputation methods were applied.

"To our knowledge, this is the first study examining the impact of elevated SII levels on the risk of atopic dermatitis in the outpatient US population. Given the varying diagnostic standards for atopic dermatitis across different countries, our findings could have significant implications for understanding and managing the condition globally," the researchers concluded.

Reference:

Ding, Q., Lin, L., Li, X., Xie, X., & Lu, T. (2024). Association between systemic immune-inflammation index and atopic dermatitis: A cross-sectional study of NHANES 2001–2006. Frontiers in Medicine, 11, 1461596. https://doi.org/10.3389/fmed.2024.1461596


Tags:    
Article Source : Frontiers in Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News